| Bioactivity | Aβ-IN-5 (Compound e12) is an orally active Aβ aggregation inhibitor. Aβ-IN-5 also inhibits AChE and BuChE with IC50 values of 21.29 μM and 1.32 μM, respectively. Aβ-IN-5 shows excellent neuroprotective effects and low neurotoxicity[1]. |
| Target | IC50: 1.32 μM (BuChE), 21.29 μM (AChE) |
| Invitro | Aβ-IN-5 (Compound e12) (25 μM) exhibits significant inhibition of Aβ aggregation with an inhibitory rate of 72%[1]. |
| In Vivo | Aβ-IN-5 (Compound e12) (15 mg/kg; p.o.) restores learning and memory function and exhibits no acute toxicity in vivo[1]. |
| Name | Aβ-IN-5 |
| CAS | 2417977-65-0 |
| Formula | C21H20N2O3 |
| Molar Mass | 348.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Liao Q, et al. Design, synthesis and biological evaluation of novel carboline-cinnamic acid hybrids as multifunctional agents for treatment of Alzheimer's disease. Bioorg Chem. 2020 Jun;99:103844. |